Clinuvel Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 05/03/2024
Clinuvel Pharmaceuticals Stock Forecast and Price Target
In recent months, notable analysts have provided yearlong price targets for Clinuvel Pharmaceuticals, with the average target coming in at $22.25. If it were to be achieved, this would result in a potential upside of approximately 49.73 percent from the most recent closing price in May, 2024. The high end is $46.30, and the low is $16.00. If you're considering investing in CUV stock, it's important to look at its competitors too.
49.73% Upside
Clinuvel Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Clinuvel Pharmaceuticals's Price has decreased from $21.07 to $0.00 – a 100.00% drop. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $43.42 – an increase of 100.00%. Over the next seven years, experts anticipate that Fair Value growth for Clinuvel Pharmaceuticals will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SHL Stock Forecast | Sonic Healthcare | Hold |
18
|
$25.94 | Buy/Sell | $34.12 | 19.51% |
| RHC Stock Forecast | Ramsay Health Care | Hold |
18
|
$50.98 | Buy/Sell | $56.32 | 9.87% |
| ANN Stock Forecast | Ansell | Hold |
16
|
$25.04 | Buy/Sell | $15.96 | -29.39% |
| SIG Stock Forecast | Sigma Healthcare | Hold |
12
|
$1.26 | Buy/Sell | $0.83 | -6.35% |
| EVT Stock Forecast | EVT | Outperform |
10
|
$11.87 | Buy/Sell | $14.00 | 3.62% |
Clinuvel Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Revenue for Clinuvel Pharmaceuticals has grown by 140.47%, going from $32.57M to $78.32M. In the following year, 0 experts forecast that Clinuvel Pharmaceuticals's Revenue will decrease by 25.04%, to $58.71M. In 2030, professionals predict that Clinuvel Pharmaceuticals's Revenue will decrease by 21.39%, to $61.57M.
.jpg)
Clinuvel Pharmaceuticals Dividend per Share Forecast for 2023 - 2025 - 2030
Clinuvel Pharmaceuticals's Dividend per Share has grown in the last three years, jumping from $0.03 to $0.05 – an increase of 66.67%. In the next year, analysts predict that Dividend per Share will reach $0.07 – an increase of 40.00%. For the next seven years, the forecast is for Dividend per Share to grow by 180.00%.
Clinuvel Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Clinuvel Pharmaceuticals's EBITDA has grown, increasing from $12.42M to $44.52M – an increase of 258.45%. In the following year, the 6 analysts surveyed believe that Clinuvel Pharmaceuticals's EBITDA will decrease by 1.39%, reaching $43.90M. Over the next seven years, the pros' prediction is EBITDAof $90.30M, which would mean a seven-year growth forecast of 102.83%.
Clinuvel Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
Clinuvel Pharmaceuticals's EBIT has increased by 260.24% In the last three years, going from $12.25M to $44.13M. The next year, 6 experts forecast that Clinuvel Pharmaceuticals's EBIT will decrease by 2.81%, reaching $42.89M. For the next seven years, the forecast is for EBIT to grow by 102.81%.
Clinuvel Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Clinuvel Pharmaceuticals's EPS has decreased from $0.33 to $0.00 – a 100.00% drop. In the coming year, analysts are expecting an increase in EPS, predicting it will reach $0.68 – an increase of 100.00%. Over the next seven years, experts anticipate that EPS growth for Clinuvel Pharmaceuticals will be 100.00%.
Site Navigation
.jpg)